Laddar...
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast canc...
Sparad:
| I publikationen: | Oncotarget |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Impact Journals LLC
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6219668/ https://ncbi.nlm.nih.gov/pubmed/30443290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26215 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|